These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 26056165)

  • 1. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.
    Mamonkin M; Rouce RH; Tashiro H; Brenner MK
    Blood; 2015 Aug; 126(8):983-92. PubMed ID: 26056165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Chen KH; Wada M; Pinz KG; Liu H; Lin KW; Jares A; Firor AE; Shuai X; Salman H; Golightly M; Lan F; Senzel L; Leung EL; Jiang X; Ma Y
    Leukemia; 2017 Oct; 31(10):2151-2160. PubMed ID: 28074066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains.
    Dai Z; Mu W; Zhao Y; Jia X; Liu J; Wei Q; Tan T; Zhou J
    Mol Ther; 2021 Sep; 29(9):2707-2722. PubMed ID: 34274536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered T cells can fight malignant T cells.
    Stauss HJ
    Blood; 2015 Aug; 126(8):927-8. PubMed ID: 26294714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA-Engineered CD5-CAR-γδT
    Zhu Z; Li H; Lu Q; Zhang Z; Li J; Wang Z; Yang N; Yu Z; Yang C; Chen Y; Lu H; Wang W; Niu T; Nie C; Tong A
    Adv Sci (Weinh); 2024 Sep; 11(35):e2400024. PubMed ID: 39013083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
    Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
    Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
    Gomes-Silva D; Srinivasan M; Sharma S; Lee CM; Wagner DL; Davis TH; Rouce RH; Bao G; Brenner MK; Mamonkin M
    Blood; 2017 Jul; 130(3):285-296. PubMed ID: 28539325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
    Dai Z; Mu W; Zhao Y; Cheng J; Lin H; Ouyang K; Jia X; Liu J; Wei Q; Wang M; Liu C; Tan T; Zhou J
    Signal Transduct Target Ther; 2022 Mar; 7(1):85. PubMed ID: 35332132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies.
    Wada M; Zhang H; Fang L; Feng J; Tse CO; Zhang W; Chen Q; Sha S; Cao Y; Chen KH; Pinz KG; Chen X; Fan XX; Jiang X; Ma Y
    Stem Cell Rev Rep; 2020 Apr; 16(2):369-384. PubMed ID: 32008159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
    Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
    J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
    Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
    Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity.
    Ma R; Woods M; Burkhardt P; Crooks N; van Leeuwen DG; Shmidt D; Couturier J; Chaumette A; Popat D; Hill LC; Rouce RH; Thakkar S; Orozco AF; Carisey AF; Brenner MK; Mamonkin M
    Cell Rep Med; 2024 Jul; 5(7):101628. PubMed ID: 38986621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells.
    Fang KK; Lee J; Khatri I; Na Y; Zhang L
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.
    Watanabe N; Mo F; Zheng R; Ma R; Bray VC; van Leeuwen DG; Sritabal-Ramirez J; Hu H; Wang S; Mehta B; Srinivasan M; Scherer LD; Zhang H; Thakkar SG; Hill LC; Heslop HE; Cheng C; Brenner MK; Mamonkin M
    Mol Ther; 2023 Jan; 31(1):24-34. PubMed ID: 36086817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
    Shi J; Zhang Z; Cen H; Wu H; Zhang S; Liu J; Leng Y; Ren A; Liu X; Zhang Z; Tong X; Liang J; Li Z; Zhou F; Huang L; Qin Y; Yang K; Zhang T; Zhu H
    J Hematol Oncol; 2021 Oct; 14(1):162. PubMed ID: 34627328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
    Liu L; Sun M; Wang Z
    Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
    Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
    Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
    Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
    Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.